clofibric acid has been researched along with l-165041 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Headey, SJ; Hughes, ML; Laguerre, A; Mohanty, B; Patil, R; Porter, CJ; Scanlon, MJ; Wielens, J; Williams, ML | 1 |
| Ammazzalorso, A; Amoroso, R; Brunetti, L; Bruno, I; Cama, A; Capone, F; Cerchia, C; De Filippis, B; Fantacuzzi, M; Ferrante, C; Florio, R; Giampietro, L; Laghezza, A; Lavecchia, A; Loiodice, F; Maccallini, C; Recinella, L; Tortorella, P; Verginelli, F | 1 |
2 other study(ies) available for clofibric acid and l-165041
| Article | Year |
|---|---|
Characterization of two distinct modes of drug binding to human intestinal fatty acid binding protein.
Topics: Fatty Acid-Binding Proteins; Fluorescent Dyes; Humans; Nuclear Magnetic Resonance, Biomolecular; Protein Binding; Spectrometry, Fluorescence | 2014 |
Novel Phenyldiazenyl Fibrate Analogues as PPAR α/γ/δ Pan-Agonists for the Amelioration of Metabolic Syndrome.
Topics: | 2019 |